Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Patients with diabetes mellitus inject insulin in different regions of the body. This study investigated the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg), a new-generation once-daily basal insulin with an ultra-long duration of action, after subcutaneous (SC) administration in different injection regions. METHODS: In this study, 20 healthy subjects received single SC doses of IDeg (0.4 U/kg; separated by 13-21 days) in the thigh, abdomen and deltoid in a randomised, open-label, single-centre, single-dose, complete crossover trial. Each dose was followed by a 24-h euglycaemic clamp and 120-h pharmacokinetic blood sampling. The obtained pharmacokinetic/pharmacodynamic profiles were extrapolated to steady state by simulation using a pharmacokinetic/pharmacodynamic model. RESULTS: Total IDeg exposure [area under the IDeg serum concentration-time curve 0-120 h after a single dose (AUCIDeg,0-120h,SD)] and maximum serum concentration [maximum IDeg serum concentration after a single dose (C max,IDeg,SD)] were higher (6-7 and 23-27 %, respectively) following a single SC dose in the deltoid or abdomen, compared with the thigh, as also observed with other insulin preparations. No statistical difference was observed in these measures between deltoid and abdominal administration. No pronounced differences were observed in the glucose-lowering effect of IDeg [area under the glucose infusion rate (GIR) curve 0-24 h after a single dose (AUCGIR,0-24h,SD) and maximum GIR after a single dose (GIRmax,SD)] when injected in the thigh, abdomen or deltoid (AUCGIR,0-24h,SD 2,572, 2,833 and 2,960 mg/kg, respectively). Simulated mean steady-state pharmacokinetic and pharmacodynamic profiles supported a flat and stable IDeg exposure and effect regardless of injection region, with comparable total glucose-lowering effects [area under the GIR curve at steady state (AUCGIR,τ,SS)] between the thigh, abdomen and deltoid. CONCLUSIONS: These findings support administering IDeg SC in the thigh, upper arm or abdominal wall without affecting IDeg absorption or effect at steady state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Overarching exclusion criteria across all trials also included smoking [24, 26] and subjects with a history of recurrent severe hypoglycaemia or hypoglycaemic unawareness [21, 22, 24, 25], again to minimise potential variables that might have a confounding influence on data interpretation.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“at simulated SS conditions, AUCIDeg,τ,SS and C max,IDeg at SS (C max,IDeg,SS) were estimated to be only ~8 and 10 % higher, respectively, following injection in the deltoid or abdomen, compared with the thigh.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“A randomised, open-label, five-period, single-centre, SD crossover trial found that there were no major differences in IDeg exposure following a single SC injection of IDeg in the deltoid, abdomen or thigh [26].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“no pronounced differences were observed in the glucose-lowering effect of IDeg [AUCGIR,0–24h,SD and maximum GIR after a SD (GIRmax,SD)] when injected in the thigh, abdomen or deltoid (AUCGIR,0–24h,SD 2,572, 2,833 and 2,960 mg/kg, respectively).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“No difference in exposure was observed between administration in the deltoid or abdomen.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [26]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“In contrast to other basal insulin preparations, which form crystals or precipitate upon SC injection [12– 15], IDeg stays in solution and forms stable multi-hexamers in the SC tissue from which IDeg monomers gradually separate, producing a slow absorption into the circulation with low day-to-day variability [11, 16,…”
ResultSelf-citationUltra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331
Self-citationGalloway, J. A., Spradlin, C. T., Nelson, R. L., Wentworth, S. M., Davidson, J. A., & Swarner, J. L. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.366 · Cited by 226
Owens, D. R., Coates, P. A., Luzio, S. D., Tinbergen, J. P., & Kurzhals, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.813 · Cited by 200
KOIVISTO, V. A., & FELIG, P. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-1-59 · Cited by 153
Evans, M., Schumm‐Draeger, P. M., Vora, J., & King, A. B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01395.x · Cited by 146
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01636.x · Cited by 143
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects
Kuerzel, G. U., Shukla, U., Scholtz, H. E., Pretorius, S. G., Wessels, D. H., Venter, C., Potgieter, M., Lang, A. M., Koose, T., & Bernhardt, E. (2003) · Current Medical Research and Opinion · doi:10.1185/030079902125001416 · Cited by 130
Insulin Preparations with Prolonged Effect
Owens, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0068 · Cited by 130
Research works printed but not linked: 2
- Kurtzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54:S426.
- Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec: twofold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia. 2011;54:S425.
Cited by
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
“Overarching exclusion criteria across all trials also included smoking [24, 26] and subjects with a history of recurrent severe hypoglycaemia or hypoglycaemic”
BackgroundMethodInfluentialSelf-citationFactors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability
Gradel, A. K. J., Porsgaard, T., Lykkesfeldt, J., Seested, T., Gram-Nielsen, S., Kristensen, N. R., & Refsgaard, H. H. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1205121 · Cited by 202
Self-citationCengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Ehtisham, S., Fairchild, J. M., Jarosz-Chobot, P. A., Ng, S. M., Paterson, M. A., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13442 · Cited by 129
Clinical use of insulin degludec
Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.002 · Cited by 73
Insulin degludec: overview of a novel ultra long‐acting basal insulin
Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12052 · Cited by 74
Metadata
- Authors
- Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T.
- Affiliations
- Profil Institute for Metabolic Research (DE)
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Nosek, Leszek
- Venue
- Clinical Drug Investigation
- Published
- 2014-08-16
- Volume
- 34
- Issue
- 9
- Pages
- 673-679
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- PMC
- PMC4143594
- OpenAlex
- W2099438726
- Semantic Scholar
- feffa0dfc4ac48cd2442a1bec0a9564d3636656f
- Cited by
- 42
- References
- 20
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 1
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Drug Investigation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Keywords
- insulin degludec, subcutaneous injection site, basal insulin, pharmacokinetics, pharmacodynamics, glucose-lowering effect, insulin absorption, euglycaemic clamp, thigh, deltoid muscle, abdomen, diabetes mellitus, ultra-long-acting insulin
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Models, Biological, Glucose Clamp Technique, Cross-Over Studies, Area Under Curve, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. https://app.cochat.ai/papers/10.1007/s40261-014-0218-x
- The paper
- Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014). Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. Clinical Drug Investigation. https://doi.org/10.1007/s40261-014-0218-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.